This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chaudhury, R. R. Search for Related Content Social Bookmarking                         What's this?

Enhancing Access to New ARV Therapies in Developing Countries

National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110 067 E-mail: dsprud{at}satyam.net.in

Recent advances in HIV drug development has opened new opportunities for preventing mother-to-child transmission and for providing treatment to those living with HIV/AIDS. As a result in Western countries antiretroviral therapy is now part of the standard of care. However, in the developing countries these drugs are beyond the reach of the majority of patients because of high costs and other logistical reasons. Therefore, ensuring access to anti-HIV drugs is now a major issue in the developing world. This paper discusses various strategies and options that can be used to enhance accessibility to these drugs. Seven steps have been proposed, including selection of drug combinations, priority groups that should receive these drugs, pooled procurement, rational prescribing and logistics, as well as steps needed to make available drugs within the TRIPS agreement framework.

Journal of Health Management, Vol. 2, No. 2, 235-243 (2000)
DOI: 10.1177/097206340000200208


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?